Evoke Pharma Inc (EVOK)
5.40
-0.32
(-5.59%)
USD |
NASDAQ |
Nov 05, 10:23
Evoke Pharma Debt to Equity Ratio: 1.876 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
June 30, 2024 | 1.876 |
March 31, 2024 | 1.430 |
December 31, 2023 | -1.938 |
September 30, 2023 | -5.722 |
June 30, 2023 | 9.287 |
March 31, 2023 | 2.352 |
December 31, 2022 | 1.224 |
September 30, 2022 | 0.9037 |
Date | Value |
---|---|
June 30, 2022 | 0.6953 |
March 31, 2022 | 2.585 |
December 31, 2021 | 1.406 |
September 30, 2021 | 1.048 |
June 30, 2021 | 0.8381 |
March 31, 2021 | 0.6401 |
December 31, 2020 | -1.588 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-5.722
Minimum
Sep 2023
9.287
Maximum
Jun 2023
1.002
Average
1.048
Median
Sep 2021
Debt to Equity Ratio Benchmarks
Repligen Corp | 0.2956 |
NovaBay Pharmaceuticals Inc | -1.128 |
Palatin Technologies Inc | 0.00 |
iBio Inc | 0.0461 |
Theriva Biologics Inc | -- |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 12.14M |
Total Liabilities (Quarterly) | 9.471M |
Shareholders Equity (Quarterly) | 2.665M |
Current Ratio | 1.281 |